Testosterone Cypionate vs AndroGel: Switching Between Them

What Are Testosterone Cypionate and AndroGel?

Testosterone cypionate is an oil-based esterified form of testosterone given by intramuscular or subcutaneous injection. AndroGel is a hydroalcoholic gel containing 1% or 1.62% testosterone applied once daily to the shoulders, upper arms, or abdomen. Both are FDA-approved for male hypogonadism. The FDA label for testosterone cypionate injection is available at accessdata.fda.gov, and AndroGel's prescribing information is indexed in the FDA database.

Mechanism and Ester Chemistry

Testosterone cypionate releases free testosterone as the ester bond is hydrolyzed after injection. The cypionate ester has a half-life of approximately 8 days, which is why weekly dosing keeps most men in a reasonable range. AndroGel delivers testosterone transdermally; absorption averages 10% of the applied dose through intact skin, with the rest lost to evaporation or remaining on the skin surface [1].

FDA Approval Status

Testosterone cypionate injection (generic and brand Depo-Testosterone) has been FDA-approved since 1979. AndroGel 1% received FDA approval in 2000, and the higher-concentration 1.62% formulation was approved in 2011. Both carry a black-box warning, though the specific warnings differ: AndroGel's warning centers on secondary exposure risk, while cypionate's addresses polycythemia and cardiovascular events in certain populations [2].

How Their Pharmacokinetics Differ

Pharmacokinetics determine how often you dose, how stable your levels are, and how quickly you can switch formulations. The two drugs behave very differently in this regard.

Testosterone Cypionate Peaks and Troughs

After a 200 mg injection of testosterone cypionate, serum total testosterone typically peaks between 400 and 1,100 ng/dL at 24 to 72 hours, then falls toward the lower end of normal or below by day 14 [1]. This peak-trough swing is the most frequently cited reason patients want to switch to a daily delivery system. Injecting 100 mg weekly instead of 200 mg biweekly substantially narrows the swing, keeping most men between 500 and 900 ng/dL through most of the dosing interval.

AndroGel Steady-State Kinetics

AndroGel produces a flatter serum testosterone curve. After the first application, levels rise within 30 minutes and reach a pharmacokinetic steady state by the second or third day of consecutive use [2]. The trade-off is that average levels are often modest. In the T-Trials (N=788 men aged 65 or older, NEJM 2016), topical testosterone gel raised serum testosterone into the normal range (500 to 900 ng/dL target) in the majority of participants who were dose-titrated correctly [3]. The trial did not compare gel directly against injectable cypionate in a head-to-head arm, so cross-formulation superiority claims are not supported by that dataset.

Half-Life Summary

| Parameter | Testosterone Cypionate | AndroGel 1.62% | |---|---|---| | Half-life | ~8 days (ester) | ~70 minutes (free T in serum) | | Time to peak | 24 to 72 hours post-injection | ~2 hours after application | | Steady-state | Reached after 3 to 4 injections | Reached after 2 to 3 days daily use | | Dosing frequency | Weekly or biweekly | Daily |

Clinical Evidence: What the T-Trials Showed

The Testosterone Trials (T-Trials) represent the most rigorous placebo-controlled data on testosterone therapy in older hypogonadal men. Published in the New England Journal of Medicine in 2016, the T-Trials enrolled 788 men aged 65 or older with serum testosterone below 275 ng/dL and at least one symptom of hypogonadism [3].

Sexual Function and Vitality Outcomes

Participants in the sexual function sub-trial showed statistically significant improvements in sexual desire and erectile function with testosterone gel versus placebo. The Physical Function Trial found a modest but significant improvement in walking distance at 6 minutes. The Vitality Trial showed improvement in energy and mood scores. The T-Trials used a testosterone gel formulation (AndroGel 1%) rather than injectable cypionate, so these specific outcome data apply directly only to gel [3].

What the T-Trials Do Not Tell Us About Cypionate

The T-Trials did not include an injectable arm. Extrapolating their outcome data to testosterone cypionate requires the assumption that raising serum T to a similar range by a different delivery route produces equivalent tissue effects. Most clinical endocrinologists consider this a reasonable working assumption based on mechanistic grounds, but the Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that "no definitive evidence demonstrates that any particular testosterone formulation is superior to another with respect to clinical outcomes" [4].

Cardiovascular Signal

The T-Trials also reported a higher rate of coronary artery plaque volume increase on CT angiography in the testosterone group versus placebo (mean difference 41 mm3, P<0.001) [3]. This finding was flagged by the FDA and contributed to the 2015 label update requiring cardiovascular risk disclosure on all testosterone products, injectable and topical alike [2].

Comparing Practicality: Injections vs. Daily Gel

Beyond pharmacokinetics, day-to-day usability shapes long-term adherence.

Injection Logistics

Testosterone cypionate requires a 21 to 23 gauge needle for drawing and a 23 to 25 gauge needle for subcutaneous injection, or a 21 to 22 gauge for intramuscular. Self-injection takes most patients under three minutes once trained. The main barriers are needle anxiety and the need to keep sterile technique. Vials must be refrigerated after opening in most climates, though the drug is stable at room temperature for 28 days per manufacturer data.

Gel Application and Transfer Risk

AndroGel is applied once daily, dries in three to five minutes, and requires no needles. The practical problem is secondary transfer. The FDA's MedWatch database includes multiple case reports of virilization in female partners and children exposed to gel via skin-to-skin contact [2]. Men with young children at home, or who share a bed with a partner before the gel dries, face a meaningful risk that cypionate simply does not create. The AndroGel prescribing information recommends covering the application site with clothing and washing hands immediately after application.

Adherence Data

Daily dosing can improve or worsen adherence depending on the individual. A 2014 analysis in the Journal of Sexual Medicine found that adherence to daily topical testosterone was approximately 70% at 12 months versus roughly 80% for biweekly injections in men who self-administered [5]. Missing a single gel application matters less than missing an injection, but missing three or four consecutive days of gel causes serum testosterone to fall back toward baseline within 72 hours.

Who Should Use Which Formulation

No single formulation is universally better. Patient profile drives the decision.

Patients Who Do Better on Testosterone Cypionate

Men who travel frequently and cannot guarantee refrigeration or consistent daily application often prefer weekly injections. Men bothered by mood swings tied to the injection cycle may benefit from weekly 100 mg dosing rather than biweekly 200 mg. Men with household contacts, particularly children under 12, should strongly prefer injectable cypionate to eliminate transfer risk entirely.

Patients Who Do Better on AndroGel

Men with needle phobia or a history of injection-site complications (abscess, granuloma) are reasonable candidates for gel. Men whose jobs or schedules make biweekly clinic visits for injection administration impractical may also benefit. Older men with poor muscle mass who are poor candidates for deep intramuscular injection sometimes absorb gel adequately, provided they are dose-titrated against measured serum T.

The Endocrine Society's Guidance

The Endocrine Society's 2018 guideline on male hypogonadism recommends individualizing the choice of formulation based on "patient preference, cost, and formulation-specific adverse effects" rather than on a hierarchical superiority ranking [4]. That guideline also specifies confirming the diagnosis with two morning serum testosterone measurements below 300 ng/dL before initiating any formulation.

How to Switch Between Testosterone Cypionate and AndroGel

Switching is a common clinical scenario. Done correctly, most men maintain adequate serum T throughout the transition with minimal symptomatic gap.

Switching from AndroGel to Testosterone Cypionate

Apply the last gel dose on day zero. Give the first cypionate injection on the same day or the following day, since the gel's transdermal reservoir clears within 24 to 72 hours of stopping. A typical starting dose is 100 mg subcutaneously or intramuscularly. Check serum total testosterone at 4 weeks, drawn as a trough (just before the next injection) if on weekly dosing, or at day 7 if on biweekly dosing.

Switching from Testosterone Cypionate to AndroGel

Begin the first gel application when serum testosterone is expected to be at or near trough, typically 7 days after a weekly injection or 12 to 14 days after a biweekly injection. Starting gel at the peak of an injection cycle risks supraphysiologic levels for 48 to 72 hours. Most physicians target a trough total T below 400 ng/dL before initiating gel to avoid this overlap effect.

Monitoring After the Switch

The following three-point monitoring framework covers most switch scenarios:

1. Baseline total testosterone drawn the day of the switch decision (confirm trough for injection patients, any-time for steady-state gel patients).
2. Follow-up total testosterone at 4 to 6 weeks on the new formulation, drawn at the pharmacokinetically appropriate time (trough for injections, 2 to 8 hours post-application for gel per Endocrine Society guidance [4]).
3. Hematocrit and hemoglobin at 3 months, given that both formulations raise erythropoiesis. The American Urological Association recommends withholding testosterone if hematocrit exceeds 54% [6].

Cost and Insurance Considerations

Cost is a real-world driver of formulation choice. Generic testosterone cypionate 200 mg/mL, 10 mL multi-dose vial, costs approximately $25, $40 at most retail pharmacies without insurance. A monthly supply (two 1 mL injections) costs under $10 in drug cost alone, though supplies (syringes, needles, alcohol swabs) add roughly $15, $20 per month.

AndroGel brand 1.62% typically lists at $400, $600 per month without insurance. Generic testosterone gel is available and costs $60, $120 per month at most pharmacies, substantially reducing the gap. Insurance coverage varies widely. Medicare Part D covers both formulations but applies different tier placements depending on the plan formulary.

Safety Profile and Monitoring for Both Formulations

Both formulations share the same class-level adverse effect profile because both deliver exogenous testosterone.

Shared Adverse Effects

Polycythemia (elevated hematocrit) occurs with both formulations, more commonly with injectable testosterone because of higher peak levels. The T-Trials reported hematocrit above 54% in 7.1% of testosterone-treated men versus 1.0% in placebo [3]. Testicular atrophy and suppression of sperm production occur with both formulations via the same hypothalamic-pituitary-gonadal axis suppression. Men wishing to preserve fertility should discuss human chorionic gonadotropin (hCG) co-administration with their prescribing physician before starting either formulation [4].

Formulation-Specific Risks

Injection-site reactions (pain, bruising, oil embolism in rare cases of intravenous accidental injection) are specific to cypionate. Skin irritation, contact dermatitis at the application site, and secondary exposure are specific to gel. Neither formulation is approved for use in men with known or suspected prostate cancer or breast cancer [2].

PSA Monitoring

Both the Endocrine Society and the American Urological Association recommend checking PSA at baseline and again at 3 to 6 months after initiation of testosterone therapy, then annually thereafter in men over 40 [4, 6]. A rise of more than 1.4 ng/mL above baseline within 12 months warrants urology referral regardless of which formulation is being used.

Practical Dosing Reference

| Scenario | Testosterone Cypionate | AndroGel 1.62% | |---|---|---| | Starting dose | 100 mg IM/SQ weekly | 40.5 mg (2 pumps) daily | | Titration increment | Increase by 25 to 50 mg/injection | Increase by 20.25 mg (1 pump) | | Maximum labeled dose | 200 mg every 2 weeks | 81 mg (4 pumps) daily | | Target total T range | 400 to 700 ng/dL (trough) | 400 to 700 ng/dL (mid-day) | | First follow-up lab | 4 weeks (trough draw) | 2 to 4 weeks (2 to 8 hr post-application) |

Dose titration should be guided by serum total testosterone levels, not symptoms alone, per Endocrine Society 2018 guideline recommendations [4].